CAR-T cell manufacturing: Major process parameters and next-generation strategies
Journal of Experimental Medicine · 05.02.2024 · 221 (2)
DOI: 10.1084/jem.20230903 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Experimental Medicine, online erschienen am 16.01.2024. Verfasst von Melanie Ayala Ceja und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Autoimmune Diseases. Die Arbeit wurde bisher 322-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Parker Institute for Cancer Immunotherapy, California Institute for Regenerative Medicine.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA, USA.
- Department of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
- Jonsson Comprehensive Cancer Center, University of California-Los Angeles , Los Angeles, CA, USA.
- Parker Institute for Cancer Immunotherapy Center at University of California-Los Angeles , Los Angeles, CA, USA.
- Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, Los Angeles, CA, USA.
ORCID-Profile: Melanie Ayala Ceja, Mobina Khericha, Caitlin M Harris, Cristina Puig-Saus, Yvonne Y Chen
Förderung
- NCI NIH HHS
- Parker Institute for Cancer Immunotherapy
- California Institute for Regenerative Medicine
- Jean and Stephen Kaplan
Zitieren
APA
Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2024). CAR-T cell manufacturing: Major process parameters and next-generation strategies. Journal of Experimental Medicine, 221(2). https://doi.org/10.1084/jem.20230903
Vancouver
Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. Journal of Experimental Medicine. 2024;221(2). doi:10.1084/jem.20230903
BibTeX
@article{AyalaCeja2024,
author = {Ayala Ceja, Melanie and Khericha, Mobina and Harris, Caitlin M and Puig-Saus, Cristina and Chen, Yvonne Y},
title = {CAR-T cell manufacturing: Major process parameters and next-generation strategies},
journal = {Journal of Experimental Medicine},
year = {2024},
volume = {221},
number = {2},
doi = {10.1084/jem.20230903}
}
EUVIMED